Implementing the ESMO recommendations for the use of circulating tumor DNA (ctDNA) assays in routine clinical application/diagnostics-Reference-Cited by-同舟云学术

Implementing the ESMO recommendations for the use of circulating tumor DNA (ctDNA) assays in routine clinical application/diagnostics

Published:2024-06-17 Issue:4 Volume:48 Page:141-151
ISSN:2567-9430
Container-title:Journal of Laboratory Medicine
language:en
Short-container-title:

Author:

Gamisch Alexander¹^ORCID,Mustafa Hans Georg¹,Haushofer Alexander²,Mustafa-Korninger Maria-Elisabeth¹

Affiliation:

1. Medilab Dr. Mustafa, Dr. Richter Labor für medizinisch-chemische und mikrobiologische Diagnostik GmbH, Molekularbiologie , Salzburg , Austria

2. Institute for Medical and Chemical Laboratory Diagnostics , Hospital Wels-Grieskirchen , Wels , Austria

Abstract

Abstract Liquid biopsy (LB) represents an advanced, minimally invasive approach that elevates the precision of oncological decision-making by identifying tumor DNA in bodily fluids. However, despite numerous endorsements from international specialty societies and working groups, implementation of LB into routine care is lagging behind due to conceptual and methodological uncertainties. This concise mini review aims to help catalyzing the translation of LB into routine care by exploring key considerations for incorporating circulating tumor DNA (ctDNA) analysis into clinical practice. Addressing eight pertinent questions from the perspective of a molecular oncology laboratory, this review synthesizes insights from the European Society for Medical Oncology (ESMO) recommendations and incorporates the latest findings from relevant literature, offering a comprehensive guide to the implementation of ctDNA assays.

Publisher

Walter de Gruyter GmbH

Link

https://www.degruyter.com/document/doi/10.1515/labmed-2024-0029/pdf

Reference40 articles.

1. Dasari, A, Morris, VK, Allegra, CJ, Atreya, C, Benson, AB, Boland, P, et al.. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper. Nat Rev Clin Oncol 2020;17:757–70. https://doi.org/10.1038/s41571-020-0392-0.

2. Rolfo, C, Mack, P, Scagliotti, GV, Aggarwal, C, Arcila, ME, Barlesi, F, et al.. Liquid biopsy for advanced NSCLC: a consensus statement from the international association for the study of lung cancer. J Thorac Oncol 2021;16:1647–62. https://doi.org/10.1016/j.jtho.2021.06.017.

3. Russo, A, Incorvaia, L, Del Re, M, Malapelle, U, Capoluongo, E, Gristina, V, et al.. The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM–SIAPEC-IAP–SIBioC–SIC–SIF Italian Scientific Societies. ESMO Open 2021;6:100164. https://doi.org/10.1016/j.esmoop.2021.100164.

4. Imai, M, Nakamura, Y, Sunami, K, Kage, H, Komine, K, Koyama, T, et al.. Expert panel consensus recommendations on the use of circulating tumor DNA assays for patients with advanced solid tumors. Cancer Sci 2022;113:3646. https://doi.org/10.1111/cas.15504.

5. Heitzer, E, Van Den Broek, D, Denis, MG, Hofman, P, Hubank, M, Mouliere, F, et al.. Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer. ESMO Open 2022;7:100399. https://doi.org/10.1016/j.esmoop.2022.100399.